HIV/AIDS PrEP Use: Insights from Recent Journal Research
MONDAY, Oct. 21, 2024 (HealthDay News) -- Preexposure prophylaxis (PrEP) use for HIV/AIDS prevention has surged between 2013 and 2023, according to a recent research letter published in the Journal of the American Medical Association. Dr. Laura M. Mann and collaborators from the U.S. Centers for Disease Control and Prevention utilized the IQVIA Real-World Longitudinal Prescription Data database to analyze prescription trends.
The findings indicate that a cumulative total of 1.1 million individuals were prescribed either oral or injectable PrEP during the study period. Notably, 88.6 percent of these prescriptions were issued to men. Annual PrEP prescriptions expanded from just 10,281 in 2013 to over 505,730 by 2023.
From January 2013 through September 2019, the monthly usage of branded tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) saw a marked increase; however, a decline was noted after the release of generic alternatives. This generic version achieved the highest monthly user share from December 2021 to December 2023. Over the entire duration, oral PrEP accounted for 99 percent of the prescriptions. Following the introduction of injectable cabotegravir in 2022, its prescriptions rose from 1.1 percent to 2.5 percent in 2023.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.